Advances for Practitioners: Cholestatic and Autoimmune Liver Disease

Product not yet rated

Recorded On: 10/23/2017

This session will highlight recent key studies in the field of cholestatic and autoimmune liver diseases. Speakers will review data on new therapies for the treatment of PBC and discuss the role of risk stratification in the management of this disease. Additionally, recent studies evaluating new biomarkers and surveillance strategies in PSC will be reviewed to determine their usefulness and applicability. Finally, the session will evaluate the evidence underlying the use of specific second line therapies in autoimmune hepatitis and a treatment algorithm will be proposed.

Christopher L. Bowlus

Dr. Christopher Bowlus obtained his medical degree at St. Louis University and completed his postgraduate training at University of California Davis and Yale University. Dr. Bowlus is Professor of Medicine and Chief of the Division of Gastroenterology and Hepatology at UC Davis. Dr. Bowlus conducts clinical and translational research in autoimmune liver diseases including primary biliary cholangitis and primary sclerosing cholangitis.

Christoph Schramm

John M. Vierling

Components visible upon registration.